None listed
Conditions
Interventions
Dietary Supplement : The subjects have taken the test or placebo product once a day (2 pills per instance: 200mg per pill) 30 minutes after the breakfast with an appropriate amount of water (Total 400
Sponsors
Glucan
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.healthy adult female of 40-70 years old with no specific diseases 2.The osteogenesis marker of Osteocalcin value is within normal range or osteoclasis marker of deoxypyridinoline value is within normal range 3.Those who heard and completely understood the detailed description of this clinical test, and wish to participate voluntarily, and made a written consent to abide by the rules 4.Those who can be monitored during the human application test period
Exclusion criteria
Exclusion criteria: 1.Those who received hormone replacement therapy, calcitonin, or bisphosphonate treatment and such within 6 months of the screening test 2.Those who were taking beta-adrenaline acceptor suppressant within 2 months of the screening test 3.Those who are taking hyperlipidemia / endocrine disease treatments, hormone product, bean-containing health functional food, etc. within 2 months of the screening test 4.Those who are taking Vitamin D, K, and Ca supplement within 4 weeks of screening test 5.Those who are taking steroid-type drug or oriental medicine that may influence bone metabolism 6.Those who have had other clinical test medicine within 1 month 7.Cancer patients with breast cancer, ovary cancer, endometrium cancer, cervical cancer, bone cancer, etc. 8.Those with diseases influencing bone metabolism (liver, kidney diseases, blood diseases, etc.) 9.Those with important history or a current disease in terms of neurology/psychology 10.Expectant mother, lactating woman, fertile woman who do not agree to undertake an appropriate contraception method (hormone contraceptive: pills, intrauterine device: loop, block contraception: femidom, intravaginal spermicide), drug addicts 11.Others deemed inappropriate by the discretion of the researcher in charge or the test representative
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| urinary DPY(Deoxypyridinoline) | — |
Secondary
| Measure | Time frame |
|---|---|
| blood OSC(osteocalcin);blood BALP(bone-specific alkaline phosphatase), ;blood CTX(C-telopeptide of type-I collagen);blood NTX(N-telopeptide of type-I collagen);blood Hyaluronic acid;urinary Ca;urinary P | — |
Countries
Korea, Republic of
Contacts
Public ContactSoo-Jin Park
Daegu Haany University
Outcome results
None listed